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Plasma cell leukemia (PCL) is a rare and aggressive plasma cell disorder, characterized by the presence of a peripheral blood
absolute plasma cell count of at least 2×109/l and more than 20% circulating plasma cells. The prognosis of PCL patients remains
poor. Even by using autologous or allogenic transplant procedures, median survival does not exceed 3 years (Saccaro et al., 2005).
Thalidomide, bortezomib and lenalidomide (Revlimid) have emerged as high active agents in the treatment of PCL (Johnston and
abdalla, 2002; Musto et al., 2007; Finnegan et al., 2006). In particular, Lenalidomide is a structural analogue of thalidomide with
similar but more potent biological activity; it is used as ﬁrst line therapy in MM (Palumbo et al., 2007; Niesvizky et al., 2007),
although information regarding its associated use with dexamethasone use as salvage therapy in PCL derives from anecdotal single
case reports (Musto et al., 2008). We would like to describe a case of primary PCL with adverse cytogenetic in which excellent
response was achieved with the combination of lenalidomide, melphalan, and prednisone as salvage therapy.
Copyright © 2009 Tommasina Guglielmelli et al. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
1.CaseReport
A 50-years-old man was diagnosed with PCL in March
2006. He was admitted due to fatigue. The full blood cell
count revealed elevated white blood cell count (25×109L
−1)
associated with the presence of 50% peripheral blood plasma
cells. Serum immunoﬁxation showed an IgGk monoclonal
component (MC) with high IgG immunoglobulin level
(10.5g/dL).
Immunophenotypingdemonstratedaplasmacellspopu-
lationCD38,CD138,CD40,CD45,CD20positiveandCD56,
CD19 negative. The results of the cytogenetic analysis per-
formed with interphase Fluorescence In Situ Hybridization
analysis showed 13q14 deletion, t(4;14) translocation, and
p53 deletion. The patient’s ISS score was 2 and, importantly,
he was diagnosed to be positive for Hepatitis B virus
(HBV) surface antigen with normal liver function. HBeAg,
HBeAb, HBCAg, and HBV Dna at diagnosis were negative.
The management decision was to perform autologous stem
cell transplantation (ASCT) following adequate stem cell
collection with cyclophosphamide and two cycles of com-
bination chemotherapy with vincristine, doxorubicin, and
dexamethasone (VAD). The patient did not respond to the
induction therapy and, therefore, he underwent two cycles
of combination chemotherapy consisting of bortezomib
(1.3mg/m2 d1 ,4 ,8 ,1 1 ) ,d o x o r u b i c i n( 2 0m gd1 . 4)a n d
dexamethasone (40mg d -2-1, 2, 3, 4). A partial response
(PR) was documented (MC component reduction 85%) and
the patients underwent autologous stem cell transplantation
with melphalan 200mg/m2 as conditioning regimen. He
achieved a very good partial response [1]. A reactivation
of HBV infection leading to an acute hepatitis (HBV
DNA >106copies/mL) was diagnosed two months after the
transplant despite antiviral therapy with lamivudine and
the patient was treated with combination antiviral therapy
with lamivudine and adefovir dipivoxil for six months until
hepatitis resolution. A tandem ASCT was excluded for the
high risk of hepatic complications. Maintenance therapy2 Journal of Oncology
with thalidomide 100mg/d was then started and carried
on for 6 months until progressive disease [2]. On May
2008 the patient relapsed with a progressive increase in MC
amount(4.3g/dL),highWBCcount(11×109L
−1)associated
with the presence of 30% peripheral blood plasma cells,
and advanced bone disease. Due to the relevant side eﬀects
observed after the ﬁrst ASCT, the patient was considered
noneligible for allogenic transplantation even if there was
an available HLA matched donor. On May 2008 the patient
started lenalidomide 25mg/d for 21d plus dexamethasone
40mg d 1–4 for a 28-d cycle for two cycles. As a stable
disease was obtained and due to the persistence of bone
pain, low dose melphalan (0.1mg/kg/d d 1–4) was added
on the third cycle in order to achieve a rapid response for
six additional melphalan-prednisone-lenalidomide (MPR)
cycles. Each MPR cycle was administered every 30–35 days
and at haematological reconstitution.
Transient grade 3-4 thrombocytopenia treated with
platelets transfusion and transient grade 2-3 neutropenia
treated with G-CSF were observed. We do not observe
thromboembolic or neurological events during MPR treat-
ment. The patient achieved a PR after 3 MPR cycles
(MC reduction 55%, absence of circulating plasma cells)
and he remained in PR for four months. On February
2009 the patient relapsed and he underwent autologous
transplantation as salvage therapy. He died on April 2009 for
progressive disease.
2. Discussion
Plasma cell leukaemia is a rare and aggressive form of
multiple myeloma characterized by very poor prognosis. The
median overall survival with conventional therapy is about
7–14 months, while even after stem cell transplantation
the outcome remains disappointing [3]. Recently, it has
been demonstrated that bortezomib may be also eﬀective
and safe in the treatment of PCL [4, 5]. A single case
report evidenced the eﬀectiveness of the association of
prednisone and lenalidomide in relapsed PCL [6]. In a
phase 2 study, the association of melphalan-prednisone-
lenalidomide (Revlimid) (MPR) was very promising in
multiple myeloma patients with 81% of patients achieved at
least a partial response, 47.6% achieved a very good partial
response, and 23.8% achieved a complete immunoﬁxation-
negative response. The EFS and OS at 1 year were 92%
and 100%, respectively. A large phase 3 international trial
comparing melphalan-prednisone with MPR is currently
ongoing.Recentliteraturesuggeststheeﬀectivenessofacom-
bination of melphalan-prednisone-lenalidomide (Revlimid)
(MPR) in plasma cell disorders, resulting in a highly eﬀective
regimen for patients noneligible for high dose therapy and
stem cells transplantation [7, 8].
To our knowledge, this is the ﬁrst reported patient
with primary PCL treated with standard dose lenalidomide
(25mg/d) plus low dose melphalan (0.1mg/kg/d d 1–4). No
severe adverse event was observed. Moreover, in our patient,
MPR regimen has demonstrated enhanced activity despite
high risk prognostic factors. We conclude that MPR is safe
and eﬀective and could be used in plasma cell leukaemia
patients in relapse and/or noneligible for autologous or
allogenic bone marrow transplantation. Moreover, MPR
regimen may be also considered in PCL as ﬁrst line therapy
or as new induction regimen in the ASCT setting.
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